| Overview |
| bs-3588R-PerCP |
| CRTC1 Polyclonal Antibody, PerCP Conjugated |
| IF |
| Human, Mouse, Rat |
| Specifications |
| PerCP |
| Rabbit |
| KLH conjugated synthetic peptide derived from human TORC1 |
| Polyclonal |
| #REF! |
| IgG |
| 1ug/ul |
| Purified by Protein A. |
| Aqueous buffered solution containing 0.01M TBS (pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol. |
| Store at -20C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles. |
| Target |
| 23373 |
| CREB regulated transcription coactivator 1; CRTC1; KIAA0616; MECT 1; Mucoepidermoid carcinoma translocated protein 1; also known as MucoEpidermoid Carcinoma Translocated 1; TORC1; Transducer of CREB protein 1; Transducer of regulated cAMP response element binding protein 1; WAMTP1. |
| which activates transcription through both consensus and variant cAMP response element (CRE) sites. MECT1 does not appear to modulate CREB1 DNA-binding activity but enhances the interaction of CREB1 with TAF4/TAFII-130. MECT1 translocates with MAML2 (MasterMind-Like Protein 2) to yield a fusion oncogene: t(11;19) (q21;p13). This translocation occurs in mucoepidermoid carcinomas, benign Warthin tumors and clear cell hidradenomas. The novel fusion product that results disrupts the Notch signaling pathway. The fusion protein consists of the N-terminus of MECT1 joined to the C-terminus of MAML2. The reciprocal fusion protein consisting of the N-terminus of MAML2 joined to the C-terminus of MECT1 has been detected in a small number of mucoepidermoid carcinomas. Multiple isoforms have been reported for the MECT1 protein. |
| Application Dilution |
| IF |
|
Powered by Bioz